Climb Bio

We believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients

[Climb Bio @ClimbBio]

$CLYM presents CLYM116 initial Phase 1 safety data and translational modeling results at @ERAkidney Congress 2026 supporting continued development #ERA2026

📈 View the poster: https://t.co/xaGqcIy45O 
🔗 Learn more: https://t.co/FAIFEjJTS1

[Climb Bio @ClimbBio]

The Trail Ahead: June ⛰️

Upcoming events:
🔷 ERA Congress | June 3–5 | Glasgow
🔷 Jefferies Healthcare Conference | June 4 | NYC
🔷 EHA Congress | June 11–15 | Stockholm

🔗 Learn more: https://t.co/ZEEkthQL9p

[Climb Bio @ClimbBio]

📍 Glasgow
$CLYM has arrived at #ERA2026 and is looking forward to connecting with the nephrology community 

🔗 Learn more about our upcoming presentation: https://t.co/ychHPDXm3x

[Climb Bio @ClimbBio]

Later today $CLYM will be participating in a fireside chat with @Jefferies 

🔗 Tune in to learn more about the trail ahead: https://t.co/m7DFVRJFzv 

#ClimbBio #TimeToClimb #Immunology #Autoimmune #Nephrology #BCell

[Climb Bio @ClimbBio]

$CLYM will be at @EHA_Hematology presenting safety, B-cell depletion, and initial platelet data from the low dose cohort from the ongoing Phase 1b/2a trial of budoprutug in previously treated patients with ITP #EHA #EHA2026

🔗 Abstract available here: https://t.co/IiAD9hlupm

[Climb Bio @ClimbBio]

ICYMI: Budoprutug and the CD19 Opportunity 

The $CLYM clinical development program is building the foundation for budoprutug’s potential long term value across multiple B cell–mediated diseases.

🔗 Listen to the full webcast here: https://t.co/4EpPNWkJhL

[Climb Bio @ClimbBio]

From alignment to action in IgAN.

At @NephCure’s IgAN Alliance Workshop #2, stakeholders built on priorities identified in the first convening, focusing on solutions to improve diagnosis, access, and care. 

Learn more: https://t.co/8FWup4M1SZ

[Climb Bio @ClimbBio]

$CLYM will be at the @ERAkidney 2026 congress presenting: 
🔹CLYM116: PK/PD modeling from NHPs to humans and initial safety data 
🔹Budoprutug: trial-in-progress poster for PrisMN, ongoing Phase 2 study of budo in pMN 

🔗 Learn more: https://t.co/funtPpwbAy

#ERA26 #pMN #IgAN

[Climb Bio @ClimbBio]

We’re seeing strong momentum around B cell-directed therapies in IgAN. At the @nkf B Cell Workshop in Dallas, discussions highlighted both the enthusiasm for targeting APRIL and the key questions around implementation as these approaches advance #IgAN #antiAPRIL #ClinicalResearch

[Climb Bio @ClimbBio]

On #ClinicalTrialsDay, we’re recognizing the patients, care partners, investigators, and advocates helping advance research.

🔗 $CLYM Ongoing Trials: https://t.co/JuO6aGEcsK 

#Autoimmune #Nephrology #BCell #ClinicalTrials #PatientEducation

[Climb Bio @ClimbBio]

Earlier today, $CLYM participated in a fireside chat with @HCWainwright.

🔗 Watch the replay to learn more about the trail ahead: https://t.co/BeLYjto5cd 

#ClimbBio #TimeToClimb #Immunology #Autoimmune #Nephrology #BCell

[Climb Bio @ClimbBio]

Today is IgAN Awareness Day! The theme is “22 Years of Hope. One Relentless Mission” for the 22 years since @IGANFoundation 's founding. Every story shared, every conversation started, and every effort to educate helps move the field forward🔗https://t.co/EBe3LkNmFU #IgANaware

[Climb Bio @ClimbBio]

$CLYM management will be participating in fireside chats with @HCWCO and @Jefferies in May and June.

🔗 Learn more here: https://t.co/g2AUMDl7Mv 

#ClimbBio #TimeToClimb #Immunology #Autoimmune #Nephrology #BCell

[Climb Bio @ClimbBio]

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates 

🔗 https://t.co/u0KhjKn31v

[Climb Bio @ClimbBio]

$CLYM Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts 

Watch here: https://t.co/zZaj439R2S

[Climb Bio @ClimbBio]

@nephcure added the PrisMN Ph2 clinical trial for people living with pMN to its Clinical Trial Finder. 

🔗Learn more: https://t.co/VWRACyoAR2  

#RareKidneyDisease #ClinicalTrials #PatientEducation

[Climb Bio @ClimbBio]

@nkf We’re proud to support this effort and look forward to the expert recommendations that will help guide future IgAN clinical trials. #IgANephropathy #IgAN #KidneyHealth (3 of 3)

[Climb Bio @ClimbBio]

We’re grateful to @nkf for hosting The Future of Clinical Trial Design in IgA Nephropathy and bringing together clinicians, scientists, regulators, industry partners, and patients to tackle pressing challenges in IgAN clinical research #IgANephropathy #IgAN #KidneyHealth (1 of 3)

[Climb Bio @ClimbBio]

@nkf With multiple novel therapies advancing in IgAN, thoughtful dialogue around endpoints, feasibility, global trial execution, and patient priorities will be critical to discuss the future of of IgAN clinical trials. #IgANephropathy #IgAN #KidneyHealth (2 of 3)

[Climb Bio @ClimbBio]

Next Week: Budoprutug and the CD19 Opportunity

A live webcast with $CLYM leadership and Dr. David Jayne on budoprutug, our investigational anti-CD19 mAb, and the CD19 opportunity. 

🔗 https://t.co/zZaj439R2S